BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD

Published: 8-Dec-2023
Research & Development

Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for a total value of 28 MUSD to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects

The project is estimated to run from late Q4 2023 until Q1 2026 and the platform is aimed to shorten time for drug development workflows. The project will run in a ramp-up phase during 2024 and the vast majority of the project will be carried out and invoiced during 2025.
 
“This agreement is a milestone for the Group and it’s our largest project to date. It also shows the strength in Biosero’s offering for laboratory automation solutions and we expect to shorten current timelines for drug development through automation”, says Maria Forss, President and CEO, BICO.

See more

You may also like

Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

Read more
The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials

Trending Articles

  1. Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
  2. Global myalgic encephalomyelitis study identifies 250+ core genes and shared biology with long COVID PrecisionLife’s large-scale genomic analysis reveals major biological drivers of ME and its overlap with long COVID, identifying dozens of drug repurposing opportunities and paving the way for more targeted clinical trials
  3. Free online course introduces fundamentals of SFC Learn how SFC can improve efficiency and reduce environmental impact
  4. GlaxoSmithKline and Oxford BioTherapeutics partner to advance antibody-based therapeutics for cancer The collaboration leverages OBT's proprietary OGAP-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets
  5. Titan Enterprises highly commended for Manufacturer of the Year at industry awards Recognition reflects the company’s investment in innovation and precision flow measurement

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Research & Development

CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration

Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development

New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research

Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development

Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery

The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development

GlaxoSmithKline and Oxford BioTherapeutics partner to advance antibody-based therapeutics for cancer

The collaboration leverages OBT's proprietary OGAP-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets
Research & Development

PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific

The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape
Manufacturing

Titan Enterprises highly commended for Manufacturer of the Year at industry awards

Recognition reflects the company’s investment in innovation and precision flow measurement
Subscribe now